Alterity Therapeutics Appoints Chief Medical Advisor to Advance ATH434 Phase 3
Alterity Therapeutics has appointed Daniel O. Claassen, M.D., M.S., as Chief Medical Advisor effective March 2026, leveraging his expertise as coordinating investigator on its Phase 2 ATH434 trial in multiple system atrophy. He will steer clinical development towards a pivotal Phase 3 study.
1. Leadership Appointment
Alterity Therapeutics announced that Daniel O. Claassen, M.D., M.S., has been named Chief Medical Advisor effective March 2026, retaining his academic position at Vanderbilt University Medical Center. This role positions him to provide strategic medical guidance as the company advances its neurodegenerative disease portfolio.
2. Professional Credentials
Claassen is a board-certified neurologist with over two decades of clinical and translational research experience in movement disorders and cognitive neurology. He coordinated the Phase 2 ATH434 trial in multiple system atrophy, authored hundreds of peer-reviewed studies, and secured competitive grants from the National Institutes of Health and other agencies.
3. ATH434 Development Path
In his new capacity, Claassen will oversee clinical trial design and execution for ATH434's pivotal Phase 3 trial in multiple system atrophy, building on clinically meaningful slowing of disease progression observed in Phase 2 studies, and support broader drug discovery initiatives targeting neurodegenerative pathologies.